RE:QuestionI agree with MM that yours is a multi billion US dollar question and it will be answered when those holding the levers determine it will happen.
If you asked what price would start to get attention from the real holders of stock here I would say attention would start to happen over $4 a share. Others would say at $8 to $10 a share. If you believe Seto then take his published USD EBITDA and a multiple in his range of 10 to 25 and wear out the batteries on your calculator. Then determine (realistically) what you would expect for your shares in Cdn$. Do share if you're so inclined.
Timing? Well - the BOD and management were given a message with the vote for directors. If achievements continue to be shabby then the vote next year may oust the bunch of them. If they do the job - and some signs seem to say they are - we'll reach the 90 patient mark for Tigris this fall sometime. Then we get to see what the redacted Baxter milestone is. Perhaps it's more than just writing a cheque as I see no reason to redact that for 3 years. Also, Baxter's shiny new KidneyCo is established and alive by end of this year to mid 2024. Tigris and EAA are heavily featured in their plans. So if we don't go for the FDA approval at 90 I wouldn't be surprised to see Baxter do a takeout offer through KidneyCo in early 2024.
What do other real shareholders think?